Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The international journal of neuropsychopharmacology 2024-02, Vol.27 (2), p.1
Hauptverfasser:	Turkoz, Ibrahim, Daskiran, Mehmet, Siddiqui, Uzma, Knight, R Karl, Johnston, Karen L, Correll, Christoph U
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!